Regulatory Effect of Qingzhenfang on Cellular Immune Function of Patients with Chronic Urticaria
10.13422/j.cnki.syfjx.20201133
- VernacularTitle:清疹方对慢性荨麻疹细胞免疫功能的调节作用
- Author:
Qiu-xiang LUO
1
;
Qiong-ping LIANG
2
;
Jian-peng YOU
3
;
Min-ling XU
2
;
Shan-qiu LIANG
2
Author Information
1. Guangxi International Zhuang Medical Hospital，Nanning 530000，China
2. Yao Medical Hospital of Jinxiu Yao Autonomous County，Laibin 545708，China
3. Guangxi University of Chinese Medicine，Nanning 530000，China
- Publication Type:Research Article
- Keywords:
chronic urticaria （plasmoby）;
Yaoyi;
Qingzhenfang;
complement;
cellular immunity;
recurrence
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(4):95-100
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of Qingzhenfang for plasmoby （chronic urticaria）， and to investigate its effect on cellular immune function. Method:One hundred and thirty-two cases patients were divided into control group and observation group evenly according to random number table. The 60 patients in control group finished the study because of 6 cases of dropout， loss of follow-up and withdrawal， and 62 patients in observation group finished the study. Patients in both groups got Yiebastine tablets， 10-20 mg/time， 1 time/day. Patients in control group additionally got Piminxiao capsule， 4 grains/time， 3 times/day， while patients in observation additionally got Qingzhenfang， 1 dose/day. The treatment continued for 8 weeks in both groups. Before the treatment， and at the second， fourth， and eighth week after treatment， scores of urticaria activity for 7 days （USA7） and total symptom score （TSS） were graded. Before and after treatment， scores of chronic urticaria quality of life scale （CU-Q2oL） and syndrome of rheumatic fever were graded. A follow-up of 3 months was conducted for the patients whose score of USA7 was less than 7 to record the recurrence. Complement 3 and 4 （C3， C4）， CD4+， CD8+ cells were detected， and Th17/ CD4+ and Treg/ CD4+， CD4+/CD8+ and Th17/Treg were calculated. Levels of peripheral blood interleukin-10 （IL-10）， IL-17 and IL-23 were detected， and safety was evaluated after the treatment. Result:At the second， fourth and eighth week after the treatment， scores of USA7， TSS， CU-Q2oL and syndrome of rheumatic fever in observation group were lower than those in the control group （P<0.01）. Levels of C3， C4， CD4+， Treg， CD4+/CD8+and IL-35 in observation group were higher than those levels detected in control group （P<0.01）， while levels of CD8+， Th17， Th17/Treg， IL-10， IL-17 and IL-23 were lower than those in the control group （P<0.01）. Recurrence rate was 25.58% （11/43） in observation group， lower than 48.48% （16/33） in control group （χ2
![]()
![]()
=4.276， P<0.05）， and the clinical efficacy in observation group was superior to that in control group （Z=2.021， P<0.05）. Conclusion:Yaoyi Qingzhenfang can control the degree of disease and improve the quality of life for patients with chronic urticaria， with superior clinical efficacy. In addition， it can reduce recurrence rate， increase the levels of C3， C4， regulate cellular immune function， and reduce immune inflammatory response， so it is worthy of further clinical research and use.
